OpenAI Offers US University Labs Free GPT-Rosalind Access
Oct 15, 2026
Biotech
OpenAI acquires Orchestra Bio to bring AI agents into drug development
Oct 20, 2026
OpenAI has acquired Orchestra Bio, a startup building AI agents for drug development, and will fold it into its Rosalind life sciences tools. Terms were not disclosed.
OpenAI has acquired Orchestra Bio, a startup building AI agents that help pharmaceutical companies manage drug development, the company told Axios in an exclusive and announced on its website. Financial terms were not disclosed.
OpenAI will integrate Orchestra's team and technology into Rosalind, its suite of AI models and tools for life sciences researchers. Orchestra's platform lets scientists delegate tasks such as monitoring studies, tracking drug development timelines and identifying potential delays to AI agents.
OpenAI introduced its GPT-Rosalind model in April and works with Novo Nordisk and Moderna on research workflows. Rival Anthropic acquired AI biotech startup Coefficient Bio for roughly $400 million in April, The Information reported, and launched Claude Science in June.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Funding
Oct 20 Reliable Robotics Adds $115 Million to Series D Oct 20 ASI Raises $325 Million at $3 Billion Valuation Oct 20 Salesforce to Acquire Braze for $5.66 Billion Oct 20 Trinity Acquires Verix to Add Tovana to TrinityEDGE Oct 20 Mural Raises $15 Million for AI Agent Payment InfrastructureMore from Life Sciences
Oct 20 Gates Foundation Updates AI Principles on Access and Safety Oct 20 MEDITECH and Lifemed AI Partner on Claims Automation Oct 20 Sophont launches Holon-S1 to predict gene activity from pathology slides Oct 20 OpenEvidence and Doximity Settle Clinical AI Legal Dispute Oct 20 Study Finds Clinical Stigma Can Skew AI Emergency TriageFree newsletter
AI Funding Brief
Market report
.png)
2025 Generative AI in Professional Services Report
Thomson Reuters
This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.
Read moreYou may also like
OpenAI Speeds Up $30 Billion Funding Round Before Anthropic IPO
Oct 20, 2026
Language Models
Opsin raises $21 million for AI agent security platform
Oct 19, 2026
Funding
Optro Launches AI Agents for Audit and Compliance
Oct 14, 2026
AI Agents
OpenAI in Early Talks to Acquire Trail of Bits
Oct 15, 2026
Acquisitions
Sopris Capital Acquires Blackford Analysis from Bayer
Oct 12, 2026
Acquisitions
Free, six days a week
Daily AI Brief: the AI news that matters, in your inbox.